Chronic Plaque Psoriasis Market is expected to double, reaching USD 36 billion by 2034

Chronic plaque psoriasis is the most common form of psoriasis, accounting for nearly 80-90% of all cases worldwide. It is a chronic autoimmune disease characterized by raised, inflamed, and scaly skin patches that significantly affect patients' quality of life. While topical therapies and phototherapy have long been standard treatments, the advent of biologics and targeted small molecules has transformed the market.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71377

With rising prevalence, increased awareness, and the approval of innovative therapies, the global chronic plaque psoriasis market is projected to grow steadily through 2034. Biologics targeting interleukins (IL-17, IL-23) and oral small molecules such as JAK inhibitors are setting new standards of care, while digital health platforms are improving treatment adherence.

Market Overview
• Market Size (2024): USD 18 billion
• Forecast (2034): USD 36 billion
• CAGR (2025-2034): ~8.5%*

• Key Growth Drivers: Rising prevalence of psoriasis, biologics adoption, improved healthcare access.

• Key Challenges: High cost of biologics, limited awareness in emerging economies, treatment adherence issues.

• Leading Players: Novartis AG, AbbVie, Johnson & Johnson (Janssen), Eli Lilly, Amgen, Pfizer, UCB Pharma, Sun Pharma.

Segmentation Analysis
By Therapy Type
• Topical Treatments (corticosteroids, vitamin D analogs, calcineurin inhibitors)
• Phototherapy
• Conventional Systemics (methotrexate, cyclosporine, acitretin)
• Biologics (IL-17, IL-23, TNF-alpha inhibitors)
• Targeted Small Molecules (JAK inhibitors, PDE4 inhibitors)

By Route of Administration
• Oral
• Topical
• Injectable (subcutaneous, intravenous)

By End Use
• Hospitals
• Dermatology Clinics
• Specialty Centers
• Homecare

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Summary: Biologics are the fastest-growing therapy class due to high efficacy and durable remission rates. However, oral targeted therapies are gaining traction due to patient convenience.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71377/chronic-plaque-psoriasis-market

Regional Analysis
• North America: Largest market share, driven by advanced healthcare systems and strong adoption of biologics. The U.S. leads globally in biologic prescriptions.
• Europe: Strong adoption in Germany, the UK, France, and Italy, supported by favorable reimbursement policies.
• Asia-Pacific: Fastest-growing region, fueled by rising prevalence, expanding healthcare infrastructure, and increasing drug approvals in Japan, China, and India.
• Middle East & Africa: Gradual adoption, limited by affordability and awareness. GCC countries represent early adopters.
• Latin America: Brazil and Mexico are emerging markets, with improving dermatology infrastructure and expanding biologic access.
Summary: While North America and Europe dominate the market in value, Asia-Pacific is projected to post the fastest CAGR through 2034, supported by demographics and healthcare investments.

Market Dynamics
Key Growth Drivers
• Rising prevalence of chronic plaque psoriasis globally.
• Expanding adoption of biologics (IL-17 and IL-23 inhibitors).
• Pipeline expansion with oral JAK and PDE4 inhibitors.
• Increasing disease awareness and patient advocacy programs.

Key Challenges
• High cost of biologics limiting access in emerging economies.
• Safety concerns with long-term immunosuppressive use.
• Poor treatment adherence due to relapse and side effects.

Latest Trends
• Development of next-generation biologics with improved safety and dosing schedules.
• Growing role of digital health solutions for treatment monitoring.
• Expansion of precision medicine approaches targeting genetic and immunological markers.
• Partnerships between pharma and payers to improve biologic affordability.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71377

Competitor Analysis
Major Players
• Novartis AG - Leading with Cosentyx (IL-17 inhibitor).
• AbbVie - Market stronghold with Skyrizi (IL-23 inhibitor) and Humira legacy.
• Johnson & Johnson (Janssen) - Tremfya (IL-23 inhibitor) driving growth.
• Eli Lilly - Expanding biologic portfolio with Taltz (IL-17 inhibitor).
• Amgen - Strong biologic presence with Enbrel.
• Pfizer - Developing JAK inhibitors and biologics pipeline.
• UCB Pharma - Active in immunology and dermatology therapies.
• Sun Pharma - Expanding dermatology and generic psoriasis treatments.
Summary: The competitive landscape is moderately consolidated, with AbbVie, Novartis, and Johnson & Johnson leading the biologics segment. However, competition is intensifying as new oral therapies and biosimilars enter the market.

Conclusion
The chronic plaque psoriasis market is evolving rapidly, transitioning from conventional systemic therapies to biologics and targeted small molecules. With an estimated CAGR of ~8.5% through 2034, the market outlook is strong, supported by rising prevalence, advanced pipelines, and growing awareness.

Key Takeaways:
• Biologics (IL-17 and IL-23 inhibitors) dominate, but JAK inhibitors are emerging fast.
• North America and Europe lead today, but Asia-Pacific will drive the highest CAGR.
• Affordability and adherence remain major challenges.
• Companies focusing on biologics innovation and patient-friendly oral therapies will capture future growth.

The next decade promises better patient outcomes, personalized treatment approaches, and broader access, making chronic plaque psoriasis one of the most dynamic markets in dermatology.

This report is also available in the following languages : Japanese (慢性プラーク乾癬市場), Korean (만성 플라크 건선 시장), Chinese (慢性斑块型银屑病市场), French (Marché du psoriasis en plaques chronique), German (Markt für chronische Plaque-Psoriasis), and Italian (Mercato della psoriasi a placche cronica), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71377/chronic-plaque-psoriasis-market#request-a-sample

Our More Reports:

Community-Acquired Bacterial Pneumonia Market
https://exactitudeconsultancy.com/reports/71735/community-acquired-bacterial-pneumonia-market

Chronic Hepatitis B Market
https://exactitudeconsultancy.com/reports/71733/chronic-hepatitis-b-market

Athlete's Foot Market
https://exactitudeconsultancy.com/reports/71731/athlete-s-foot-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.